It was shown to suppress IL-1β maturation and caspase 1 activation in PBMCs of Ibrutinib treated cancer patients and is currently under phase 1 trials in combination with lenalidomide and 5′-Azacytidine for MDS (NCT03359460 and NCT02553941). Here, CASP1 is linked to myelodysplastic syndrome.